Foamix Pharmaceuticals Ltd (FOMX) Can’t Be More Safe. Trades Significantly Higher

September 17, 2017 - By Louis Casey

The stock of Foamix Pharmaceuticals Ltd (NASDAQ:FOMX) is a huge mover today! The stock increased 4.20% or $0.21 on September 15, reaching $5.21. About 127,069 shares traded or 67.18% up from the average. Foamix Pharmaceuticals Ltd (NASDAQ:FOMX) has declined 30.16% since September 17, 2016 and is downtrending. It has underperformed by 46.86% the S&P500.
The move comes after 7 months positive chart setup for the $194.99 million company. It was reported on Sep, 17 by Barchart.com. We have $5.42 PT which if reached, will make NASDAQ:FOMX worth $7.80M more.

Analysts expect Foamix Pharmaceuticals Ltd (NASDAQ:FOMX) to report $-0.44 EPS on November, 21.They anticipate $0.25 EPS change or 131.58 % from last quarter’s $-0.19 EPS. After having $-0.44 EPS previously, Foamix Pharmaceuticals Ltd’s analysts see 0.00 % EPS growth.

Foamix Pharmaceuticals Ltd (NASDAQ:FOMX) Ratings Coverage

Among 2 analysts covering Foamix Pharmaceuticals (NASDAQ:FOMX), 2 have Buy rating, 0 Sell and 0 Hold. Therefore 100% are positive. Foamix Pharmaceuticals had 3 analyst reports since August 25, 2015 according to SRatingsIntel. The stock has “Hold” rating by Zacks on Tuesday, August 25.

More notable recent Foamix Pharmaceuticals Ltd (NASDAQ:FOMX) news were published by: Seekingalpha.com which released: “High-Potential Pipeline And Sufficient Cash Make Foamix Pharmaceuticals A …” on March 23, 2017, also Globenewswire.com with their article: “Foamix Reports Second Quarter 2017 Financial Results and Provides Business Update” published on August 08, 2017, Prnewswire.com published: “Foamix Pharmaceuticals First Quarter Financial Results Conference Call …” on April 26, 2017. More interesting news about Foamix Pharmaceuticals Ltd (NASDAQ:FOMX) were released by: Seekingalpha.com and their article: “Foamix Pharmaceuticals’ (FOMX) CEO Dave Domzalski on Q2 2017 Results …” published on August 09, 2017 as well as Seekingalpha.com‘s news article titled: “Foamix Pharmaceuticals’ (FOMX) CEO Dov Tamarkin on Q4 2016 Results – Earnings …” with publication date: February 22, 2017.

Foamix Pharmaceuticals Ltd. is a clinical-stage pharmaceutical company. The company has market cap of $194.99 million. The Firm is engaged in the development and commercialization of foam formulations, using its technology, which includes its foam platforms. It currently has negative earnings. It is focused on developing and commercializing its minocycline foam for the treatment of acne, rosacea and other skin conditions.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.